Michel Dahan - 13 May 2024 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Signature
/s/ Carolyn Rucci, attorney-in-fact for Michel Dahan
Issuer symbol
AKBA
Transactions as of
13 May 2024
Net transactions value
-$43,898
Form type
4
Filing time
14 May 2024, 16:04:58 UTC
Previous filing
01 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Sale $43,898 -34,840 -4.9% $1.26 672,092 13 May 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.
F2 This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2023.